A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer

Autor:	Alex R. Menter, Olugbenga Olowokure, Mohamedtaki Abdulaziz Tejani, Manoj Maniar, Steven J. Cohen, A. J. Scott, P. Phillip, Antonio Jimeno, R. Nazemzadeh, Joaquina Baranda, Paul T. Fanta, R. Bajaj, Autumn J. McRee, Dara L. Aisner, Bert H. O'Neil, L. Coveler, W. W. Ma, Wells A. Messersmith, Jordan Berlin, M. Cusnir, J. Boles, Venu Bathini, R. Maguire, Francois Wilhelm, C. L. Gomes, Jonathan K. Cho, Lawrence Leichman, Deirdre Jill Cohen, J. Radford, J. Granfortuna, Louis Fehrenbacher, M. Rarick
Jazyk:	angličtina
Rok vydání:	2015
Předmět:	Oncology medicine.medical_specialty business.industry Rigosertib Hematology Corrigenda Gemcitabine law.invention Randomized controlled trial law Internal medicine Metastatic pancreatic cancer medicine In patient business medicine.drug
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b115c24d8ac4bcfff80a573a4206362 https://europepmc.org/articles/PMC5266090/ Zobrazit plný text záznamu